<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93942">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01717755</url>
  </required_header>
  <id_info>
    <org_study_id>NL33550.100.10</org_study_id>
    <secondary_id>NHS2010B151</secondary_id>
    <secondary_id>2010-023507-95</secondary_id>
    <nct_id>NCT01717755</nct_id>
  </id_info>
  <brief_title>Basilar Artery International Cooperation Study</brief_title>
  <acronym>BASICS</acronym>
  <official_title>Basilar Artery International Cooperation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erik van der Hoeven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BASICS Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Antonius Hospital</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Recently our study group reported the results of the Basilar Artery International
      Cooperation Study (BASICS), a prospective registry of patients with an acute symptomatic
      basilar artery occlusion (BAO). Our observations in the BASICS registry underscore that we
      continue to lack a proven treatment modality for patients with an acute BAO and that current
      clinical practice varies widely. Furthermore, the often-held assumption that intra-arterial
      treatment (IAT) is superior to intravenous thrombolysis (IVT) in patients with an acute
      symptomatic BAO is challenged by our data. The BASICS registry was observational and has all
      the limitations of a non-randomised study. Interpretation of results is hampered by the lack
      of a standard treatment protocol for all patients who entered the study.

      Objective: Evaluate the efficacy and safety of additional IAT after IVT in patients with
      basilar artery occlusion.

      Study design: Randomised, multi-centre, open label, controlled phase III, treatment trial

      Study population: Patients, aged 18 through 85 years, with CTA or MRA confirmed basilar
      occlusion treated with IVT.

      Target number of participants: 750.

      Intervention: Patients will be randomised between additional IAT followed by maximum
      supportive care versus maximum supportive care alone. IVT has to be initiated within 4.5
      hours from estimated time of basilar artery occlusion and IAT within 6 hours.

      Main study parameters/endpoints: Favourable outcome at day 90 defined as a modified Rankin
      Score (mRS - functional scale) of 0-3.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">January 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Favourable outcome</measure>
    <time_frame>day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Favourable outcome at day 90 defined as a modified Rankin Score (mRS - functional scale) of 0-3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Excellent outcome</measure>
    <time_frame>day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Excellent outcome at day 90 defined as a modified Rankin Score (mRS - functional scale) of 0-2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score</measure>
    <time_frame>day 90</time_frame>
    <safety_issue>No</safety_issue>
    <description>Modified Rankin Score - not dichotomized.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS</measure>
    <time_frame>pre IVT, pre randomization, 24h post treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>National Institutes of Health Stroke Scale (NIHSS - acute assessment scale) at timepoints:
directly pre intravenous thrombolysis
directly pre randomization (post intravenous thrombolysis)
at 24 hours +- 6 hours post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>day 90 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>EQ-5D (quality of life) at day 90 and at 12 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Recanalization</measure>
    <time_frame>24 hours ± 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Recanalization at 24 hours ± 6 hours, by CT angiography.</description>
  </other_outcome>
  <other_outcome>
    <measure>Volume of cerebral infarction</measure>
    <time_frame>24 hours ± 6 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Volume of cerebral infarction on NCCT and CTA source images.</description>
  </other_outcome>
  <other_outcome>
    <measure>SICH</measure>
    <time_frame>24 hours ± 6 hours.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Symptomatic intracranial hemorrhage at 24 hours CT imaging ± 6 hours.</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>90 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mortality at 90 days.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">750</enrollment>
  <condition>Basilar Artery Thrombosis</condition>
  <condition>Basilar Artery Embolism</condition>
  <condition>Stroke of Basilar Artery</condition>
  <condition>Stroke</condition>
  <condition>Cerebrovascular Disorders</condition>
  <arm_group>
    <arm_group_label>No additional intra-arterial treatment.</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Intravenous thrombolysis followed by maximum supportive care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Additional intra-arterial treatment.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous thrombolysis followed by intra-arterial treatment and maximum supportive care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Intra-arterial treatment</intervention_name>
    <description>The choice of the IA strategy will be made by the treating neurointerventionalist. IA treatment options available will be any of the following devices or thrombolytics, depending on local approval and experience; the Merci and Trevo thrombus-removal devices, Penumbra, Solitaire, infusion of rt-PA combined with an application of low-intensity ultrasound at the site of the occlusion via the EKOS Micro-Infusion Catheter, infusion of alteplase or urokinase via a standard micro-catheter. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis.</description>
    <arm_group_label>Additional intra-arterial treatment.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms and signs compatible with ischemia in the basilar artery territory and an
             NIHSS ≥ 10 at time of randomization.

          -  Basilar artery occlusion confirmed by CTA or MRA.

          -  Age18 through 85 years (i.e., candidates must have had their 18th birthday, but not
             had their 86th birthday).

          -  Initiation of IV rt-PA within 4.5 hours of estimated time of basilar artery
             occlusion. (Estimated time of basilar artery occlusion is defined as time of onset of
             acute symptoms leading to clinical diagnosis of basilar artery occlusion or if not
             known last time patient was seen normal prior to onset of these symptoms).

          -  Initiation of IA therapy should be feasible within 6 hours of estimated time of
             basilar artery occlusion.

        Exclusion Criteria:

          -  Pre-existing dependency with mRankin ≥3.

          -  Females of childbearing potential who are known to be pregnant and/or lactating or
             who have positive pregnancy tests on admission.

          -  Patients who require hemodialysis or peritoneal dialysis.

          -  Other serious, advanced, or terminal illness.

          -  Any other condition that the investigator feels would pose a significant hazard to
             the patient if IA therapy is initiated.

          -  Current participation in another research drug treatment protocol (patient cannot
             start another experimental agent until after 90 days).

          -  Informed consent is not or cannot be obtained.

          -  Lesion consistent with hemorrhage of any degree.

          -  Significant cerebellar mass effect or acute hydrocephalus.

          -  Bilateral extended brainstem ischemia.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W J Schonewille, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Antonius Hospital Nieuwegein</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wouter Schonewille, MD</last_name>
    <phone>+31 6 41285149</phone>
    <email>w.schonewille@antoniusziekenhuis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erik van der Hoeven, MD</last_name>
    <phone>+31 6 47490060</phone>
    <email>e.van.der.hoeven@antoniusziekenhuis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrea Zini, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jeanette Hofmeijer, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julie Staals, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth Hospital</name>
      <address>
        <city>Tilburg</city>
        <state>Noord Brabant</state>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paul de Kort, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <state>Utrecht</state>
        <zip>3430 EM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wouter Schonewille, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MCH Westeinde</name>
      <address>
        <city>The Hague</city>
        <state>Zuid-Holland</state>
        <zip>2512 VA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jelis Boiten, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitary Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jaap Kappelle, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lausanne</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrik Michel, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://basicstrial.com</url>
    <description>Website BASICS trial</description>
  </link>
  <reference>
    <citation>Schonewille WJ, Wijman CA, Michel P, Rueckert CM, Weimar C, Mattle HP, Engelter ST, Tanne D, Muir KW, Molina CA, Thijs V, Audebert H, Pfefferkorn T, Szabo K, Lindsberg PJ, de Freitas G, Kappelle LJ, Algra A; BASICS study group. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol. 2009 Aug;8(8):724-30. Epub 2009 Jul 3.</citation>
    <PMID>19577962</PMID>
  </reference>
  <reference>
    <citation>Greving JP, Schonewille WJ, Wijman CA, Michel P, Kappelle LJ, Algra A; BASICS Study Group. Predicting outcome after acute basilar artery occlusion based on admission characteristics. Neurology. 2012 Apr 3;78(14):1058-63. doi: 10.1212/WNL.0b013e31824e8f40. Epub 2012 Mar 21.</citation>
    <PMID>22442438</PMID>
  </reference>
  <reference>
    <citation>Vergouwen MD, Compter A, Tanne D, Engelter ST, Audebert H, Thijs V, de Freitas G, Algra A, Jaap Kappelle L, Schonewille WJ. Outcomes of basilar artery occlusion in patients aged 75 years or older in the Basilar Artery International Cooperation Study. J Neurol. 2012 Nov;259(11):2341-6. doi: 10.1007/s00415-012-6498-2. Epub 2012 Apr 18.</citation>
    <PMID>22527236</PMID>
  </reference>
  <reference>
    <citation>Puetz V, Khomenko A, Hill MD, Dzialowski I, Michel P, Weimar C, Wijman CA, Mattle HP, Engelter ST, Muir KW, Pfefferkorn T, Tanne D, Szabo K, Kappelle LJ, Algra A, von Kummer R, Demchuk AM, Schonewille WJ; Basilar Artery International Cooperation Study (BASICS) Group. Extent of hypoattenuation on CT angiography source images in basilar artery occlusion: prognostic value in the Basilar Artery International Cooperation Study. Stroke. 2011 Dec;42(12):3454-9. doi: 10.1161/STROKEAHA.111.622175. Epub 2011 Sep 29.</citation>
    <PMID>21960577</PMID>
  </reference>
  <reference>
    <citation>Arnold M, Fischer U, Compter A, Gralla J, Findling O, Mattle HP, Kappelle LJ, Tanne D, Algra A, Schonewille WJ; BASICS Study Group. Acute basilar artery occlusion in the Basilar Artery International Cooperation Study: does gender matter? Stroke. 2010 Nov;41(11):2693-6. Epub 2010 Oct 14.</citation>
    <PMID>20947845</PMID>
  </reference>
  <reference>
    <citation>Schonewille WJ, Wijman CA, Michel P, Algra A, Kappelle LJ; BASICS Study Group. The basilar artery international cooperation study (BASICS). Int J Stroke. 2007 Aug;2(3):220-3.</citation>
    <PMID>18705948</PMID>
  </reference>
  <reference>
    <citation>Schonewille W, Wijman C, Michel P; BASICS investigators. Treatment and clinical outcome in patients with basilar artery occlusion. Stroke. 2006 Sep;37(9):2206; author reply 2207. Epub 2006 Aug 10.</citation>
    <PMID>16902170</PMID>
  </reference>
  <reference>
    <citation>Vergouwen MD, Algra A, Pfefferkorn T, Weimar C, Rueckert CM, Thijs V, Kappelle LJ, Schonewille WJ; on behalf of the Basilar Artery International Cooperation Study (BASICS) Study Group. Time is Brain(stem) in Basilar Artery Occlusion. Stroke. 2012 Nov;43(11):3003-3006. Epub 2012 Sep 18.</citation>
    <PMID>22989501</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 26, 2012</lastchanged_date>
  <firstreceived_date>October 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>St. Antonius Hospital</investigator_affiliation>
    <investigator_full_name>Erik van der Hoeven</investigator_full_name>
    <investigator_title>E.J.R.J. van der Hoeven, MD</investigator_title>
  </responsible_party>
  <keyword>basilar</keyword>
  <keyword>stroke</keyword>
  <keyword>mechanical</keyword>
  <keyword>thrombolysis</keyword>
  <keyword>intra-arterial</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
